IN THE CLAIMS

- 1. (Currently amended) A pharmaceutical composition useful for treating hematological cancer in a mammal which comprises an effective amount of a purified an arsenic sulfide compound and a pharmaceutically acceptable carrier or excipient.
 - 2. (Cancel)
- 3. (Currently amended) A pharmaceutical composition suitable for oral delivery to a human which comprises an effective amount of <u>a purified</u> an arsenic sulfide compound <u>and a pharmaceutically acceptable carrier or exciplent</u>.
 - 4. (Cancel)
- 5. (Original) The pharmaceutical composition of claim 1, wherein said mammal is a human.
- 6. (Original) The pharmaceutical composition of claim 1, wherein the arsenic sulfide compound is selected from the group consisting of As₂S₂, As₂S₃, As₂S₅ and As₄S₄.
- 7. (Original) The pharmaceutical composition of claim 6, wherein the arsenic sulfide compound is As₄S₄.
- 8. (Original) The pharmaceutical composition of claim 1, wherein the amount of said arsenic sulfide compound is from about 100 mg to about 2 g.
- 9. (Original) The pharmaceutical composition of claim 2, wherein the pharmaceutically acceptable carrier or excipient is a plant semen.
- 10. (Original) The pharmaceutical composition of claim 9, wherein the plant semen is seman platycladi.
- 11. (Original) The pharmaceutical composition of claim 1, further comprising an effective amount of an arsenious compound, wherein the arsenic sulfide compound and the arsenious compound are not the same compound.

- 12. (Original) The pharmaceutical composition of claim 11, wherein the arsenious compound is selected from the group consisting of As₂S₂, As₂S₃, As₄S₄ and As₂O₃.
- 13. (Original) The pharmaceutical composition of claim 1, further comprising an effective amount of a therapeutic agent selected from the group consisting of mustard compounds, nitrogen mustard, chliorambucil, melphalan, cyclophosphamide busulfan, 6-mercaptopurine, 6-thioguanine, cytarabine, cytosine arabinoside, 5-fluorouracil, floxuridine, methotrexate, vincristine, vinblastine, taxol, etoposide, temiposide, dactinomycin, daunorubicin, doxorubicin, epirubicin, mitoxantron, bleomycin, mitomycin, cisplatin carboplatin, estramustine phosphate, hydroxyurea, BCNU, procarbazine, VM-26 (vumon), interferons and all-trans retinoic acid.
- 14. (Original) A pharmaceutical composition useful for treating hematological cancer in a mammal which comprises an effective amount of realgar and a pharmaceutically acceptable carrier or excipient.

15.-55. (Canceled)

- 56. (Previously added) The pharmaceutical composition according to claim 1, wherein said pharmaceutical composition contains less than 0.15% arsenic trioxide.
- 57. (Previously added) The pharmaceutical composition according to claim 1, wherein said pharmaceutical composition contains less than 0.1% arsenic trioxide.
- 58. (New) The pharmaceutical composition according to claim 13, wherein said pharmaceutical composition contains less than 0.15% arsenic trioxide.
- 59. (New) The pharmaceutical composition according to claim 13, wherein said pharmaceutical composition contains less than 0.1% arsenic trioxide.